Research Analysts Offer Predictions for Neogen Q3 Earnings

Neogen Co. (NASDAQ:NEOG) – Research analysts at Zacks Research reduced their Q3 2025 EPS estimates for shares of Neogen in a research note issued to investors on Tuesday, January 28th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.12 for the quarter, down from their prior estimate of $0.14. The consensus estimate for Neogen’s current full-year earnings is $0.41 per share. Zacks Research also issued estimates for Neogen’s Q4 2025 earnings at $0.13 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.52 EPS.

Neogen (NASDAQ:NEOG) last posted its earnings results on Friday, January 10th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The business had revenue of $231.30 million during the quarter, compared to analyst estimates of $227.16 million. During the same quarter last year, the company earned $0.11 EPS. The company’s quarterly revenue was up .7% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $13.00 target price (down previously from $16.50) on shares of Neogen in a research report on Tuesday, January 21st. Guggenheim initiated coverage on Neogen in a report on Thursday, December 19th. They issued a “buy” rating and a $15.00 price objective for the company.

Neogen Stock Performance

Shares of NASDAQ NEOG opened at $11.50 on Thursday. The company has a quick ratio of 2.46, a current ratio of 3.77 and a debt-to-equity ratio of 0.33. The firm’s 50-day moving average price is $12.58 and its 200-day moving average price is $14.73. Neogen has a 52-week low of $10.72 and a 52-week high of $18.58.

Insider Buying and Selling at Neogen

In other news, CEO John Edward Adent purchased 23,035 shares of the stock in a transaction on Thursday, January 16th. The shares were acquired at an average price of $11.03 per share, with a total value of $254,076.05. Following the completion of the acquisition, the chief executive officer now directly owns 269,164 shares of the company’s stock, valued at $2,968,878.92. This trade represents a 9.36 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO David H. Naemura acquired 14,800 shares of Neogen stock in a transaction dated Thursday, January 16th. The stock was purchased at an average cost of $11.11 per share, with a total value of $164,428.00. Following the completion of the purchase, the chief financial officer now owns 61,434 shares of the company’s stock, valued at approximately $682,531.74. This represents a 31.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.13% of the stock is owned by corporate insiders.

Institutional Trading of Neogen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can raised its position in shares of Neogen by 77.1% during the second quarter. Bank of Montreal Can now owns 78,633 shares of the company’s stock valued at $1,266,000 after buying an additional 34,234 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Neogen in the second quarter worth about $293,000. Squarepoint Ops LLC purchased a new stake in shares of Neogen in the second quarter worth about $444,000. AQR Capital Management LLC bought a new position in shares of Neogen in the 2nd quarter valued at about $907,000. Finally, Millennium Management LLC purchased a new position in Neogen in the second quarter worth about $19,338,000. Institutional investors own 96.73% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.